OncoPrecision

PreComb

This company develops a precision oncology platform using patient-derived microtumour models and automated analysis to predict drug responses for biopharmaceutical firms and clinical institutions.

Oncosyne

This company develops patient-derived tumoroid drug screening platforms for pharmaceutical firms and oncologists to improve drug discovery and personalised cancer treatment.

Orakl Oncology

This company develops a predictive platform using patient tumor avatars and data to help pharmaceutical firms accelerate and de-risk cancer drug development.

Pear Bio

The company develops a precision medicine platform using microfluidic chips and computer vision to predict cancer treatment efficacy for oncologists and pharmaceutical researchers.

Xilis

Xilis develops miniature patient-derived tumour models for precision oncology and drug discovery, serving clinicians and pharmaceutical companies.

Organo-ID

The company develops 3D organoid models and drug response tests for cancer patients and pharmaceutical researchers to improve personalised medicine and treatment efficacy.

Oncobit

This company develops precision diagnostic assays and cloud-based monitoring software for clinicians to track cancer markers and therapy response in oncology patients.

Anaveon

The company develops precision biologics and engineered antibodies to treat patients with cancer and autoimmune diseases.